Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
- Conditions
- Stage III Rectal Cancer AJCC v7Rectal AdenocarcinomaStage II Rectal Cancer AJCC v7
- Interventions
- Drug: CapecitabineDrug: FluorouracilRadiation: Intensity-Modulated Radiation TherapyDrug: LeucovorinDrug: OxaliplatinBiological: PembrolizumabDrug: Veliparib
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 363
- Registration Number
- NCT02921256
- Locations
- 🇺🇸
Island Urology, Honolulu, Hawaii, United States
🇺🇸Queen's Medical Center, Honolulu, Hawaii, United States
🇺🇸Straub Clinic and Hospital, Honolulu, Hawaii, United States
Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced Rectal Cancer
- Conditions
- Rectal Adenocarcinoma
- Interventions
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2018-08-13
- Target Recruit Count
- 25
- Registration Number
- NCT02919878
- Locations
- 🇸🇦
Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
- Conditions
- Malignant Neoplasm of BreastMalignant Neoplasms of Digestive OrgansMalignant Neoplasms of Mesothelial and Soft TissueAdvanced CancerMalignant Neoplasms of Bone and Articular CartilageMalignant Neoplasms of Eye Brain and Other Parts of Central Nervous SystemMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Independent (Primary) Multiple SitesMalignant Neoplasms of Urinary TractMalignant Neoplasms of Lip Oral Cavity and Pharynx
- Interventions
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02915172
Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer
- Conditions
- Rectal Cancer
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 25
- Registration Number
- NCT02910843
- Locations
- 🇨🇭
St. Claraspital Basel, Basel, Switzerland
🇨🇭Universitätsspital Basel, Basel, Switzerland
🇨🇭Inselspital Bern, Bern, Switzerland
Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 41
- Registration Number
- NCT02901301
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Target Recruit Count
- 170
- Registration Number
- NCT02897050
- Locations
- 🇨🇳
Second Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
🇨🇳Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
- Conditions
- HER2-expressing Cancers
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 279
- Registration Number
- NCT02892123
- Locations
- 🇺🇸
Hoag Family Cancer Institute, Newport Beach, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Metronomic Versus Conventional Chemotherapy in as Maintenance Treatment in mCRC
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT02893540
- Locations
- 🇨🇳
Shanghai Rui Jin Hospital, Shanghai, Shanghai, China
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
- Conditions
- Recurrent Colorectal CarcinomaStage IV Colorectal Cancer AJCC v7Stage IVA Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7Metastatic Colorectal CarcinomaRefractory Colorectal Carcinoma
- Interventions
- Drug: AtezolizumabBiological: BevacizumabDrug: CapecitabineOther: PlaceboOther: Laboratory Biomarker Analysis
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 133
- Registration Number
- NCT02873195
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
- Conditions
- Gastric CancerGastroesophageal Junction CancerEsophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2031
- Registration Number
- NCT02872116
- Locations
- 🇯🇵
Local Institution - 0122, Minato-ku, Tokyo, Japan
🇬🇷Local Institution - 0017, Nea Kifissia, Attikí, Greece
🇵🇱Local Institution - 0016, Lublin, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.